Related Experiment Video

Updated: Jun 29, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K

Optimising PrEP uptake and use in Peru: no time to lose!

Luis Menacho1, Kelika A Konda2, Leonid Lecca3

  • 1Instituto de Medicina Tropical Alexander Von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.

The Lancet. HIV
|March 27, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.3K

Related Concept Videos

Factors Influencing Drug Absorption: Presystemic Elimination01:24

Factors Influencing Drug Absorption: Presystemic Elimination

215
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
215
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

254
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
254

Articles linked to this work by shared authors, journal, and citation graph.

"The First Thing I Must do is Become Undetectable": Examining U=U Awareness and the HIV Care Continuum Among Gay, Bisexual, and Other Men Who Have Sex With Men Living With HIV in Lima, Peru.

Journal of the International Association of Providers of AIDS Care·2026

Social Media Messaging to Reduce HIV-Related Stigma Among Young Adults in Peru: A Randomized Controlled Study.

Journal of the International AIDS Society·2026

Preferences for mHealth Features to Support Engagement in the HIV Preexposure Prophylaxis Cascade Among Men Who Have Sex With Men in Peru: Cross-Sectional Online Survey.

JMIR public health and surveillance·2026

A Qualitative Descriptive Study of the Drivers, Perpetuators, and Impacts of Stigma Among Youth Living with HIV in Lima, Peru.

AIDS and behavior·2026

Preferences for HIV testing among partners of transgender women in Lima, Peru: a discrete choice experiment.

Journal of acquired immune deficiency syndromes (1999)·2026

Evaluating the potential health and economic impacts of chlamydia vaccination strategies in the United States: a mathematical modeling and cost-effectiveness simulation study.

Lancet regional health. Americas·2026

Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

The lancet. HIV·2026

Evolving understanding of Kaposi sarcoma and associated diseases in the ART era.

The lancet. HIV·2026

Interventions to improve viral suppression and adherence to antiretroviral therapy among people living with HIV: a systematic review and network meta-analysis.

The lancet. HIV·2026

Does U=U apply during breastfeeding? An urgent research priority.

The lancet. HIV·2026

Durability of HIV viral suppression in South Africa: a national cohort study.

The lancet. HIV·2026

HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial.

The lancet. HIV·2026

Antenatal Hepatitis B screening in pregnancy: Prevention of mother-to-child transmission strategy in Kedah, Malaysia.

The Medical journal of Malaysia·2026

Priority-setting in TB programme planning: guiding an equitable and effective response.

IJTLD open·2026

Lessons learned from implementing a large-scale contact investigation and TB preventive treatment project in India.

IJTLD open·2026

Assessing public health threats: An overview of coordinated threat assessment at the Public Health Agency of Canada.

Canada communicable disease report = Releve des maladies transmissibles au Canada·2026

Using mobile phone Re-call notification as a primary care practice to improve vaccination uptake for children under five in baghdad, Iraq, 2022.

Journal of public health research·2026

Using a consensus-based approach to build a threat assessment tool for use in a Canadian federal public health setting.

Canada communicable disease report = Releve des maladies transmissibles au Canada·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us